Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Acid phosphatase.

M O Henneberry, G Engel, J T Grayhack

    The Urologic Clinics of North America
    |October 1, 1979
    PubMed
    Summary
    This summary is machine-generated.

    Prostatic acid phosphatase (PAP) is a key tumor marker for prostate cancer. Newer immunologic techniques may change how we understand its role in diagnosing and staging the disease.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Spin-orbit-coupled fractional oscillators and trapped Bose-Einstein condensates.

    Physical review. E·2024
    Same author

    Assessing venous thrombus in renal cell carcinoma: preliminary results for unenhanced 3D-SSFP MRI.

    Clinical radiology·2018
    Same author

    How well do you know your monkey TB model?

    Journal of medical primatology·2012
    Same author

    Implementation of the quality management system improves postoperative pain treatment: a prospective pre-/post-interventional questionnaire study.

    British journal of anaesthesia·2012
    Same author

    Differential-effects of fibroblast coculture on mcf-7 and mda-231 breast-carcinoma cell invasion through matrigel.

    Oncology reports·2011
    Same author

    Limited invasive capacity of plt plus ras transformed rat fibrosarcoma cells effective in experimental metastasis.

    International journal of oncology·2011
    Same journal

    An Unprecedented Era of Innovation in Non-Muscle-Invasive Bladder Cancer.

    The Urologic clinics of North America·2026
    Same journal

    Hubert Humphrey's Bladder Cancer: If He Could Have Time Traveled, Would that Have Changed the Outcome?

    The Urologic clinics of North America·2026
    Same journal

    Key Clinical Trials Shaping the Future of Superficial High-Risk Bladder Cancer Management.

    The Urologic clinics of North America·2026
    Same journal

    Future Directions: Artificial Intelligence and Digital Tools in Bladder Cancer Care.

    The Urologic clinics of North America·2026
    Same journal

    Economic Considerations in the Management of Superficial Bladder Cancer.

    The Urologic clinics of North America·2026
    Same journal

    Patient-Centered Approaches to Non-Muscle-Invasive Bladder Cancer Care.

    The Urologic clinics of North America·2026
    See all related articles

    Area of Science:

    • Biochemistry
    • Oncology
    • Clinical Chemistry

    Background:

    • Acid phosphatase (AP) is a lysosomal enzyme found in various tissues, notably the prostate.
    • Prostatic carcinoma cells often retain high AP concentrations, leading to its use as a tumor marker.
    • Elevated serum AP levels in patients with prostate cancer have been historically linked to disease progression.

    Purpose of the Study:

    • To review the role of serum acid phosphatase as a tumor marker for prostate cancer.
    • To discuss advancements in measurement techniques and their potential impact on clinical interpretation.
    • To reevaluate the clinical significance of serum AP levels in light of new methodologies.

    Main Methods:

    • Review of existing literature on acid phosphatase measurement and clinical applications.

    Related Experiment Videos

  • Discussion of traditional enzymatic assays versus newer immunologic techniques (radioimmunoassay, counterimmunoelectrophoresis).
  • Analysis of the historical and evolving interpretation of serum AP levels in prostate cancer staging and prognosis.

    • Main Results:

    • Various methods exist for measuring AP, with a shift towards more sensitive immunologic assays.
    • The clinical significance of serum AP levels is under continuous reevaluation.
    • Newer techniques may alter current concepts regarding AP's role as a prostate cancer tumor marker.

    Conclusions:

    • Accurate interpretation of serum AP requires consideration of patient status, sample handling, and assay methodology.
    • The traditional understanding of serum AP as solely indicative of extraprostatic disease may be challenged by advanced techniques.
    • Further evaluation of newer immunologic assays is necessary to fully understand their impact on prostate cancer diagnostics.